Zacks Research Analysts Boost Earnings Estimates for NKTR

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at Zacks Research increased their Q1 2025 earnings estimates for Nektar Therapeutics in a research report issued to clients and investors on Wednesday, January 29th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.21) per share for the quarter, up from their prior estimate of ($0.22). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.84) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.86) EPS.

Several other equities analysts have also recently issued reports on NKTR. Piper Sandler began coverage on Nektar Therapeutics in a research note on Monday, November 4th. They issued an "overweight" rating and a $7.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $6.50 price target on shares of Nektar Therapeutics in a research note on Monday, January 13th. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 price objective on the stock. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $4.08.

Nektar Therapeutics Trading Down 7.8 %

NASDAQ:NKTR traded down $0.06 during midday trading on Monday, reaching $0.70. The company had a trading volume of 1,712,408 shares, compared to its average volume of 1,546,378. The stock's fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.15. Nektar Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.93. The firm has a market capitalization of $129.31 million, a price-to-earnings ratio of -0.83 and a beta of 0.58.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $24.12 million during the quarter, compared to the consensus estimate of $15.54 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. During the same quarter in the previous year, the firm posted ($0.19) earnings per share.

Insider Activity at Nektar Therapeutics

In related news, insider Mark Andrew Wilson sold 33,402 shares of the company's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the sale, the insider now owns 351,892 shares in the company, valued at $316,702.80. This represents a 8.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the firm's stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now directly owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock valued at $149,878 in the last ninety days. Insiders own 3.71% of the company's stock.

Institutional Investors Weigh In On Nektar Therapeutics

Several hedge funds have recently made changes to their positions in the business. Valence8 US LP purchased a new stake in Nektar Therapeutics during the 3rd quarter valued at approximately $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $41,000. XTX Topco Ltd purchased a new position in Nektar Therapeutics in the 3rd quarter valued at $46,000. Moloney Securities Asset Management LLC increased its stake in Nektar Therapeutics by 42.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 14,895 shares during the period. Finally, HB Wealth Management LLC raised its position in Nektar Therapeutics by 44.0% during the 4th quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 19,600 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.